Database : MEDLINE
Search on : Sialorrhea [Words]
References found : 1320 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 132 go to page                         

  1 / 1320 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29508455
[Au] Autor:Palma JA; Kaufmann H
[Ad] Address:Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, New York, USA.
[Ti] Title:Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.
[So] Source:Mov Disord;33(3):372-390, 2018 Mar.
[Is] ISSN:1531-8257
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Dysfunction of the autonomic nervous system afflicts most patients with Parkinson disease and other synucleinopathies such as dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure, reducing quality of life and increasing mortality. For example, gastrointestinal dysfunction can lead to impaired drug pharmacodynamics causing a worsening in motor symptoms, and neurogenic orthostatic hypotension can cause syncope, falls, and fractures. When recognized, autonomic problems can be treated, sometimes successfully. Discontinuation of potentially causative/aggravating drugs, patient education, and nonpharmacological approaches are useful and should be tried first. Pathophysiology-based pharmacological treatments that have shown efficacy in controlled trials of patients with synucleinopathies have been approved in many countries and are key to an effective management. Here, we review the treatment of autonomic dysfunction in patients with Parkinson disease and other synucleinopathies, summarize the nonpharmacological and current pharmacological therapeutic strategies including recently approved drugs, and provide practical advice and management algorithms for clinicians, with focus on neurogenic orthostatic hypotension, supine hypertension, dysphagia, sialorrhea, gastroparesis, constipation, neurogenic overactive bladder, underactive bladder, and sexual dysfunction. © 2018 International Parkinson and Movement Disorder Society.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.1002/mds.27344

  2 / 1320 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29475576
[Au] Autor:Sridharan K; Sivaramakrishnan G
[Ad] Address:Department of Pharmacology and Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain. Electronic address: skannandr@gmail.com.
[Ti] Title:Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials.
[So] Source:J Clin Neurosci;, 2018 Feb 20.
[Is] ISSN:1532-2653
[Cp] Country of publication:Scotland
[La] Language:eng
[Ab] Abstract:Sialorrhea is a common distress associated with certain neurological disorders. The aim of this study is to compare the pharmacological agents used for treating sialorrhea by network meta-analysis. Electronic databases were searched for randomized clinical trials comparing active drugs with either placebo or other active drugs. Total drooling scores was the primary outcome measure. Inverse variance heterogeneity model was used for both direct and mixed treatment comparison analysis. Twenty one studies were included in the systematic review and 15 in the meta-analysis. Compared to placebo, benztropine, botulinum toxins A and B are associated with a significant reduction in the frequency and severity of drooling both in the overall neurological disorders as well as for children with cerebral palsy. Only botulinum toxin A and B were associated with significant therapeutic effects in Parkinson's disease. Benztropine and botulinum toxins A and B were observed to be effective in reducing sialorrhea associated with neurological disorders.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180224
[Lr] Last revision date:180224
[St] Status:Publisher

  3 / 1320 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29460161
[Au] Autor:Tiigimäe-Saar J; Tamme T; Rosenthal M; Kadastik-Eerme L; Taba P
[Ad] Address:Department of Maxillofacial Surgery, Tartu University Hospital, Tartu, Estonia. janne.tiigimae-saar@kliinikum.ee.
[Ti] Title:Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A.
[So] Source:Neurol Sci;, 2018 Feb 19.
[Is] ISSN:1590-3478
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:Patients with Parkinson's disease (PD) are compromised by poor oral condition due to oropharyngeal bradykinesia, dysphagia, and the side effects of treatment. Intrasalivary gland injections of Botulinum neurotoxin type A (BNT-A) have been known to treat sialorrhea effectively in these patients. However, the decreased amount of saliva reduces self-cleaning ability that deteriorates oral hygiene and increases dental caries. The aim of this study was to determine the changes in the oral microflora and saliva in patients with PD treated for sialorrhea by means of sonography-controlled BNT-A injections into the bilateral parotid and submandibular glands. Altogether, 38 persons participated in the study: 12 PD patients who were injected with BNT-A for treatment of sialorrhea and passed salivary tests before and 1 month after the injections; and 13 PD patients and 13 healthy subjects who were not injected with BNT-A and passed salivary tests once. The condition of oral health was measured by the amount of saliva, salivary flow rate, and salivary composition. A good outcome with a significant decrease in salivary flow rate occurred at 1-month follow-up in the BNT-A-treated group while no significant change was found in salivary composition. BNT-A treatment did not change the Streptococcus mutans levels in saliva but there was statistically significant increase in levels of Lactobacilli. BNT-A injections can effectively treat sialorrhea while considering the change of oral microflora, and the patients should be under dentists' care more frequently. EudraCT clinical trial number: 2015-000682-30.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[St] Status:Publisher
[do] DOI:10.1007/s10072-018-3279-4

  4 / 1320 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29432648
[Au] Autor:Cifuentes M; Del Barrio-Díaz P; Vera-Kellet C
[Ad] Address:Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
[Ti] Title:Pilocarpine and Artificial Saliva for the Treatment of Xerostomia and Xerophthalmia of Sjögren's Syndrome: A double blind control trial.
[So] Source:Br J Dermatol;, 2018 Feb 12.
[Is] ISSN:1365-2133
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Sjögren's Syndrome (SS) is associated with xerostomia and xerophthalmia. Pilocarpine stimulates the secretion of saliva. OBJECTIVES: Investigate and compare the efficacy of pilocarpine and artificial saliva as symptomatic treatments for xerostomia and xerophthalmia in patients with SS. PATIENTS AND METHODS: A double-blind, randomized, controlled study was performed. 72 patients with SS were assigned randomly to receive ten drops of pilocarpine (5 mg) or 10 drops of artificial saliva, orally, t.i.d.for 12 weeks. Patients were evaluated at baseline and periodically throughout the study by whole saliva and tear flow for global assessment of their dryness as well as for any adverse effects. RESULTS: Patients receiving pilocarpine had a statistically significant improvement in their salivary flow (p< 0.0001), lachrymal flow (p< 0.0001), and their subjective global assessment (p< 0.0001), compared with patients on artificial saliva. The most common side effects were sialorrhea and nausea. LIMITATIONS: As the pilocarpine was in solution (drops), it was possible for the dosage to become inaccurate. CONCLUSIONS: Pilocarpine is more effective than artificial saliva for enhancing salivary and lachrymal secretion in patients with SS. This is the first study comparing the efficacy of pilocarpine and artificial saliva as treatments for xerostomia and xerophthalmia in SS. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180212
[Lr] Last revision date:180212
[St] Status:Publisher
[do] DOI:10.1111/bjd.16442

  5 / 1320 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29224753
[Au] Autor:Marinone S; Gaynor W; Johnston J; Mahadevan M
[Ad] Address:Department of Paediatric Otolaryngology - Head and Neck Surgery, Starship Children's Health, Park Road, Grafton, Auckland, 1023, New Zealand. Electronic address: smarinone@adhb.govt.nz.
[Ti] Title:Castillo Morales Appliance Therapy in the treatment of drooling children.
[So] Source:Int J Pediatr Otorhinolaryngol;103:129-132, 2017 Dec.
[Is] ISSN:1872-8464
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To evaluate the efficacy of Castillo Morales Appliance Therapy (CMAT) in reducing the severity and frequency of problematic drooling in children. METHODS: A de-identified extraction of all hospital morbidity records belonging to patients with drooling who underwent treatment with CMAT was performed between June 22, 2000 and April 12, 2016. Data were obtained from Starship Children's Hospital clinical records department. Demographic, diagnostic, and procedural data were included. Severity and frequency of drooling was quantified using the Thomas-Stonell and Greenberg classification method. RESULTS: There were fifty-three children less than 17 years of age who were treated with CMAT for the indication of problematic drooling between June 22, 2000 and April 12, 2016. 72% (n = 38) of patients had a reduction in the severity and frequency of drooling with CMAT. Mean follow up was 51 months. These patients did not require further treatment for drooling with botulinum toxin or surgery. Within this group, 63% (n = 24) of patients had significant improvement in drooling as per the Thomas-Stonell and Greenberg classification method (p = 0.024). CONCLUSIONS: Children who underwent CMAT for drooling were less likely to require further treatment with botulinum toxin or surgery. This result suggests that the use of CMAT in children with problematic drooling confers benefit.
[Mh] MeSH terms primary: Activator Appliances
Sialorrhea/therapy
[Mh] MeSH terms secundary: Adolescent
Botulinum Toxins, Type A/therapeutic use
Child
Child, Preschool
Female
Follow-Up Studies
Hospitals, Pediatric
Humans
Male
Retrospective Studies
Salivary Glands/surgery
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Name of substance:EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Entry month:1801
[Cu] Class update date: 180104
[Lr] Last revision date:180104
[Js] Journal subset:IM
[Da] Date of entry for processing:171212
[St] Status:MEDLINE

  6 / 1320 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29243262
[Au] Autor:Hughes A; Choi S
[Ad] Address:Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital.
[Ti] Title:Does intraglandular injection of botulinum toxin improve pediatric sialorrhea?
[So] Source:Laryngoscope;, 2017 Dec 15.
[Is] ISSN:1531-4995
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 171215
[Lr] Last revision date:171215
[St] Status:Publisher
[do] DOI:10.1002/lary.27051

  7 / 1320 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29026848
[Au] Autor:Islam MS; You MJ
[Ad] Address:Laboratory of Veterinary Parasitology, College of Veterinary Medicine and Bio-safety Research Centre, Chonbuk National University, Jeonju, Republic of Korea.
[Ti] Title:Drug Induced Sialorrhea and Microfluidic-Chip-Electrophoretic Analysis of Engorged Adult Female Tick Saliva of (Acari: Ixodidae).
[So] Source:J Arthropod Borne Dis;11(1):10-18, 2017 Mar.
[Is] ISSN:2322-1984
[Cp] Country of publication:Iran
[La] Language:eng
[Ab] Abstract:BACKGROUND: The aim of the present study was to induce salivation in longicornis to increase saliva production and to characterize the collection of proteins present in the collected saliva using on-chip-electrophoresis. METHODS: Saliva of adult female engorged was collected by treatment with 0.2% dopamine hydrochloride. All protein samples were characterized by SDS-PAGE electrophoresis using a microfluidic High Sensitivity Protein Assay 250 kit by 2100 Bioanalyzer (Agilent Technologies, USA) under non-reducing conditions. RESULTS: The average salivary protein concentration was 0.169 µg/µl/tick and saliva secretion decreased with increased time of tick detachment from the host. Saliva secretion volume increased to 3.56 µl in the group of ticks with a body weight between 301-350 mg as compared to higher and lower body weight groups. On-chip-electrophoresis results show 13 distinct bands ranging from 9.9 to 294 kDa. CONCLUSION: Based on molecular weight, the putative salivary proteins are comprised of proline-rich proteins, triabin, apyrase members of the 12-kDa protein family, platelet inhibitors and anti-inflammatory proteins as tick saliva contains anti-inflammatory components.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171017
[Lr] Last revision date:171017
[St] Status:PubMed-not-MEDLINE

  8 / 1320 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28964285
[Au] Autor:Kay-Rivest E; Khendek L; Bernard G; Daniel SJ
[Ad] Address:Department of Pediatric Otolaryngology - Head and Neck Surgery, Montreal Children's Hospital, McGill University Health Center, Montreal, Quebec, Canada.
[Ti] Title:Pediatric leukodystrophies: The role of the otolaryngologist.
[So] Source:Int J Pediatr Otorhinolaryngol;101:141-144, 2017 Oct.
[Is] ISSN:1872-8464
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:BACKGROUND: Leukodystrophies consist of degenerative neurogenetic diseases often associated with comorbidities that extend beyond the neurological system. Despite their impacts on patients' quality of life and risks of complications, head and neck symptomology is poorly reported in the literature. The objective of this study was to identify and quantify the main head and neck complaints among a cohort of patients diagnosed with leukodystrophies and define the role of the otolaryngologist as part of a multidisciplinary team for treating these patients. METHODS: During the First Canadian National Conference on Leukodystrophies held at the Montreal's Children Hospital, a cohort of 12 patients diagnosed with leukodystrophies were recruited and evaluated by a multidisciplinary team. An otolaryngology-focused assessment was done through history and physical examination, and included a screening questionnaire for 23 common otolaryngology issues. If families reported a history of sialorrhea, a validated questionnaire (Drool Quality of Life Assessment Questionnaire (DroolQoL)) was subsequently distributed. Results from the questionnaires were then compiled and analyzed. RESULTS: Of the 12 recruited patients, 83% (10/12) were known to an otolaryngologist. Drooling affected 67% (8/12) of patients although only 37.5% (3/8) of patients had undergone medical or surgical therapies for this issue. Four patients experienced at least one aspiration pneumonia. 58% (7/12) of the patients had dysphagia, of whom 43% (3/12) were fed exclusively via gastrostomy tube and 28% (2/7) required thickening of feeds. Two patients, despite suspicion of dysphagia and aspiration, had never undergone evaluation. As for otologic issues, it was noted that 25% (3/12) of patients had a history of pressure equalizing tubes (PETs) and one patient had a history of hearing loss. CONCLUSION: Head and neck comorbidities affect children with leukodystrophies. Therefore, the otolaryngologist should be part of the multidisciplinary team, specifically for the management of dysphagia and sialorrhea.
[Mh] MeSH terms primary: Deglutition Disorders/etiology
Neurodegenerative Diseases/complications
Neurodegenerative Diseases/therapy
Sialorrhea/etiology
[Mh] MeSH terms secundary: Adolescent
Canada
Child
Child, Preschool
Female
Gastrostomy
Hospitals, Pediatric
Humans
Infant
Male
Otolaryngologists
Quality of Life
Retrospective Studies
Sialorrhea/complications
Surveys and Questionnaires
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171023
[Lr] Last revision date:171023
[Js] Journal subset:IM
[Da] Date of entry for processing:171002
[St] Status:MEDLINE

  9 / 1320 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28933983
[Au] Autor:Mikami DLY; Furia CLB; Welker AF
[Ad] Address:a Departamento de Pós-Graduação em Ciência e Tecnologia em Saúde , Universidade de Brasília (UNB) , Campus Ceilândia, Brasília, Brazil.
[Ti] Title:Addition of Kinesio Taping of the orbicularis oris muscles to speech therapy rapidly improves drooling in children with neurological disorders.
[So] Source:Dev Neurorehabil;:1-6, 2017 Sep 21.
[Is] ISSN:1751-8431
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To evaluate the effects of Kinesio Taping (KT) of the orbicularis oris muscles as an adjunct to standard therapy for drooling. METHODS: Fifteen children with neurological disorders and drooling received speech therapy and twice-weekly KT of the orbicularis muscles over a 30-day period. Drooling was assessed by six parameters: impact on the life of the child and caregiver; severity of drooling; frequency of drooling; drooling volume (estimated by number of bibs used); salivary leak; and interlabial gap. Seven markers of oral motor skills were also assessed. RESULTS: KT of the orbicularis oris region reduced the interlabial gap. All oral motor skills and almost all markers of drooling improved after 15 days of treatment. CONCLUSION: In this sample of children with neurological disorders, adding KT of the orbicularis oris muscles to speech therapy caused rapid improvement in oral motor skills and drooling.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1709
[Cu] Class update date: 170921
[Lr] Last revision date:170921
[St] Status:Publisher
[do] DOI:10.1080/17518423.2017.1368729

  10 / 1320 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28837826
[Au] Autor:Cardoso F
[Ad] Address:Movement Disorders Unit, Neurology Service, Internal Medicine Department, The Federal University of Minas Gerais, Brazil. Electronic address: cardosofe@terra.com.br.
[Ti] Title:Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.
[So] Source:Toxicon;, 2017 Aug 23.
[Is] ISSN:1879-3150
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The aim of this article is to provide a review of the use of injections of botulinum toxin in the management of selected symptoms and signs of Parkinson's disease and other forms of parkinsonism. Sialorrhea is defined as inability to control oral secretions, resulting in excessive saliva in the oropharynx. There is a high level of evidence for the treatment of sialorrhea in parkinsonism with injections of different forms of botulinum toxin type A as well as botulinum toxin type B. Tremor can be improved by the use of botulinum toxin injections but improved tremor control often leads to concomitant motor weakness, limiting its use. Levodopa induced dyskinesias are difficult to treat with botulinum toxin injections because of their variable frequency and direction. Apraxia of eyelid opening, a sign more commonly seen in progressive supranuclear palsy and other tauopathies, often improves after botulinum toxin injections. Recent data suggest that regardless of the underlying mechanism, pain in parkinsonism can be alleviated by botulinum toxin injections. Finally, freezing of gait, camptocormia and Pisa syndrome in parkinsonism almost invariably fail to respond to botulinum toxin injections.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1708
[Cu] Class update date: 170827
[Lr] Last revision date:170827
[St] Status:Publisher


page 1 of 132 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information